The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $10.61

Today's change+1.12 +11.80%
Updated May 27 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Vanda Pharmaceuticals Inc

Nasdaq: VNDA
Last

(U.S.) $10.61

Today's change+1.12 +11.80%
Updated May 27 4:00 PM -4GMT. Delayed by at least 15 minutes.

Vanda Pharmaceuticals Inc Hits New 100-day High

Vanda Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$1.12 or 11.80% to (U.S.)$10.61 and setting a new 100-day high. Over the last five days, shares have gained 10.58% and 13.96% year to date. Shares have outperformed the S&P 500 by 5.68% during the last year.

Key company metrics

  • Open(U.S.) $9.87
  • Previous close(U.S.) $9.49
  • High(U.S.) $10.65
  • Low(U.S.) $9.85
  • Bid / Ask(U.S.) $9.51 / (U.S.) $11.25
  • YTD % change+13.96%
  • Volume1,994,712
  • Average volume (10-day)741,985
  • Average volume (1-month)628,940
  • Average volume (3-month)566,234
  • 52-week range(U.S.) $6.91 to (U.S.) $14.50
  • Beta1.66
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.98
Updated May 27 4:00 PM -4GMT. Delayed by at least 15 minutes.
S&P TSX0.40%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue33322828
Total other revenue--------
Total revenue33322828
Gross profit27262222
Total cost of revenue6676
Total operating expense46473833
Selling / general / administrative29291818
Research & development89106
Depreciation / amortization3333
Interest expense (income), net operating--------
Unusual expense (income)--0----
Other operating expenses, total--------
Operating income-12-15-10-5
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-12-15-9-5
Income after tax-12-15-9-5
Income tax, total--------
Net income-12-15-9-5
Total adjustments to net income--------
Net income before extra. items-12-15-9-5
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-12-15-9-5
Inc. avail. to common incl. extra. items-12-15-9-5
Diluted net income-12-15-9-5
Dilution adjustment------0
Diluted weighted average shares43434242
Diluted EPS excluding extraordinary itemsvalue per share-0.29-0.35-0.22-0.13
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.29-0.35-0.22-0.13
R